CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY)
Clinical trials for CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY) explained in plain language.
Never miss a new study
Get alerted when new CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY) trials appear
Sign up with your email to follow new studies for CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weekly shot could replace IV drips for nerve disease
Disease control Recruiting nowThis study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C…
Matched conditions: CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY)
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks Efgartigimod's Real-World impact on CIDP patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The…
Matched conditions: CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY)
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC